Bandingkan Harga & Kinerja Repower Asia Indonesia Tbk. (REAL) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Repower Asia Indonesia Tbk. dan Organon Pharma Indonesia Tbk.: Repower Asia Indonesia Tbk. diperdagangkan di Rp50 (kapitalisasi pasar 331,68 M, volume 24 jam 80,3 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Repower Asia Indonesia Tbk. jauh lebih besar — sekitar 3,2× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| REAL | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 331,68 M | 104,4 M |
Volume | 80,3 rb | — |
Lot | 803 | — |
Perputaran | 4,02 jt | — |
Harga Rata-rata | 50 | — |
Nilai Transaksi | 4,02 jt | — |
Harga Ekuilibrium Indikatif | 50 | — |
Volume Ekuilibrium Indikatif | 8 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Repower Asia Indonesia Tbk.
PT Repower Asia Indonesia Tbk (the Company) was established based on Notarial Deed No. 04 of Titik Krisna Murti Wikaningsih, S.H., M.KN., dated March 13, 2011, a Notary in Bekasi.
Selengkapnya di halaman REAL →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
